Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
3
×
life sciences
3
×
national blog main
alnylam pharmaceuticals
aminolevulinic acid
boston
boston blog main
boston top stories
fda
givosiran
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
cannabidiol
dravet syndrome
epidiolex
fen-phen
fenfluramine
gw pharmaceuticals
lennox-gastaut syndrome
onpattro
patisiran
paul matteis
san francisco
san francisco blog main
san francisco top stories
stifel financial
zogenix
What
drug
medicine
3
×
pharmaceuticals
3
×
ago
alnylam
data
fda
interference
market
rna
rnai
second
seek
speedy
weeks
approval
approved
battle
cannabis
cleared
derivative
epilepsy
far
form
gw
gw’s
indicated
marijuana
nasdaq
new
nod
ok
quick
rare
sets
won’t
zogenix
Language
Current search:
xconomy.com
×
medicine
×
" life sciences "
×
pharmaceuticals
×
drugs
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug